HIFU TECHNOLOGY
PLATFORMS EXPLAINED
HIFU encompasses multiple distinct hardware platforms — from China's high-volume HAIFU and JC systems for abdominal cancers, to MRI-integrated ExAblate for fibroids and bone, transrectal Ablatherm and Sonablate for prostate cancer, and Echopulse and SONICTAC for thyroid and breast. Choosing the right platform matters as much as choosing the right treatment.
analyticsAt a Glance
- check_circleHAIFU (Chongqing) and JC systems dominate Chinese clinical practice — treating liver, pancreas, kidney, uterine fibroids, and bone at hundreds of centres
- check_circleExAblate (InSightec) is the global MRgFUS leader — used for fibroids, bone metastases, and transcranial neurological applications
- check_circleAblatherm and Sonablate are the established transrectal prostate HIFU platforms — CE-marked and used globally
- check_circlePlatform selection should be guided by indication, availability, and whether MR thermometry is required for your specific lesion
Why Platform Choice Matters in HIFU
All HIFU systems use focused ultrasound to destroy tissue — but the frequency, transducer design, guidance modality, cooling mechanism, and software differ fundamentally between platforms. These differences determine which tumour sites can be treated, how precisely treatment can be monitored, what infrastructure is required, and what the all-in cost to the patient will be. Selecting the wrong platform for a given indication is not simply a technical inconvenience — it directly affects treatment safety and outcome.
“Asking 'which HIFU centre should I go to' without knowing which HIFU system that centre operates is like choosing a hospital for surgery without asking whether they have the relevant surgical specialty.”
Guidance Modality: Ultrasound vs MRI
Ultrasound-guided HIFU (USgHIFU) uses real-time B-mode ultrasound to visualise the treatment zone — monitoring tissue echogenicity changes as a proxy for thermal effect. MRI-guided HIFU (MRgFUS) integrates MR thermometry — directly measuring focal temperature in real time. MRgFUS is more expensive and infrastructure-intensive but provides a safety margin that USgHIFU cannot match for precision-critical applications such as spinal bone metastases and transcranial neurological targets.
China's HIFU Ecosystem: Scale and Diversity
China has the world's largest installed base of HIFU systems — driven by domestic manufacturing (HAIFU, Mianyang Sonic Tech), high clinical demand, and favourable regulatory pathways for novel interventional technologies. The HAIFU JC and Model-JM series alone have treated over 100,000 patients at Chinese centres. This scale translates directly to operator experience that international patients can access.
Major HIFU Platforms: Technical Comparison
A structured reference comparing the principal HIFU systems across the parameters most relevant to clinical decision-making and patient selection.
| System | Manufacturer | Guidance | Primary Indications | Key Feature | Availability |
|---|---|---|---|---|---|
| HAIFU JC / Model-JM | Chongqing HAIFU Medical Technology, China | USgHIFU — diagnostic ultrasound | Liver, pancreas, kidney, uterine fibroids, bone, soft tissue | Water bath immersion; largest global volume; 100,000+ procedures | |
| JC-200 Focused Ultrasound | Mianyang Sonic Technology, China | USgHIFU — diagnostic ultrasound | Liver, kidney, pancreas, abdominal tumours | Similar to HAIFU; widely used in South and Southwest China | |
| ExAblate Body / 2100 | InSightec, Israel | MRgFUS — full MR thermometry | Uterine fibroids, bone metastases, breast, adenomyosis | FDA-cleared for fibroids and bone; gold-standard MR thermometry | |
| ExAblate Neuro | InSightec, Israel | tcMRgFUS — MR thermometry + CT skull map | Essential tremor, Parkinson's tremor, OCD, neuropathic pain | 1,024-element phased array; FDA-approved; skull density compensation | |
| Ablatherm FUSION | EDAP TMS, France | USgHIFU — transrectal ultrasound | Prostate cancer (whole-gland and focal) | CE-marked; robotic transrectal positioning; large European registry | |
| Sonablate 500 | HistoSonics / SonaCare Medical, USA | USgHIFU — transrectal ultrasound | Prostate cancer (whole-gland and focal) | Real-time tissue change monitoring (TCM); US-based operator experience | |
| Echopulse | Theraclion, France | USgHIFU — ultrasound integrated | Thyroid nodules, breast fibroadenoma | CE-marked; compact office-based system; dedicated thyroid protocol | |
| SONICTAC | SonaCare Medical, USA | USgHIFU — ultrasound | Thyroid nodules | FDA 510(k) cleared; compact; thyroid-specific | |
| Profound TULSA-PRO | Profound Medical, Canada | MRgFUS — transurethral; MR thermometry | Prostate cancer (whole-gland and partial) | Transurethral rather than transrectal; real-time MR thermometry prostate |
China's HIFU Landscape: What International Patients Should Know
China is home to the world's most extensive clinical HIFU infrastructure — with domestic manufacturers, regulatory pathways that enabled early adoption, and institutional experience that translates into operator skill levels that are difficult to find elsewhere at comparable cost.
HAIFU: The Global Volume Leader
The Chongqing HAIFU system — developed by Professor Feng Wu at Chongqing Medical University in the 1990s — is the world's highest-volume HIFU platform. It operates in a water bath, uses diagnostic ultrasound for guidance, and is used to treat liver cancer, pancreatic cancer, uterine fibroids, kidney cancer, and bone metastases. The platform's clinical series form the largest single-system evidence base for non-prostatic oncological HIFU anywhere in the world.
MRgFUS in China: ExAblate at Academic Centres
InSightec ExAblate Body and ExAblate Neuro systems are installed at selected major Chinese academic medical centres — including Peking University Third Hospital (tremor), PLA General Hospital, and Sun Yat-sen University Hospital. These centres perform MRgFUS for uterine fibroids, bone metastases, and transcranial neurological applications at costs substantially below equivalent programmes in the US or UK.
Prostate HIFU in China: Ablatherm and Sonablate Programmes
Both Ablatherm and Sonablate prostate HIFU systems are installed at Chinese urology departments — particularly at tertiary academic hospitals in Beijing, Shanghai, and Guangzhou. Chinese urologists trained in European HIFU programmes have established protocols for whole-gland and focal prostate ablation with outcomes data now being published from Chinese institutional series.
Matching Your Indication to the Right HIFU Platform
Use this quick reference to identify which platform is most appropriate for your specific condition — and which system type to ask about when evaluating a centre.
| Your Condition | Recommended Platform Type | Ask the Centre For |
|---|---|---|
| Uterine fibroids — fertility-critical or posterior | ExAblate Body MRgFUS (preferred) or HAIFU JC | NPV ratio achieved; MR thermometry availability; T2 signal type accepted |
| Uterine fibroids — standard access, cost-sensitive | HAIFU JC / Mianyang USgHIFU | Annual fibroid volume; operator experience with posterior/fundal lesions |
| Prostate cancer — focal therapy | Ablatherm FUSION or Sonablate 500 (transrectal) | Number of focal HIFU procedures per year; MpMRI-HIFU fusion capability |
| Prostate cancer — whole-gland | Ablatherm FUSION, Sonablate 500, or TULSA-PRO | PSA nadir outcomes data; pad-free continence rates at this centre |
| Liver HCC or metastases | HAIFU JC or JC-200 (water bath USgHIFU) | Annual liver HIFU volume; TACE+HIFU protocol availability |
| Pancreatic cancer — pain / local control | HAIFU JC with respiratory gating | Pancreatic-specific HIFU experience; respiratory gating system available |
| Bone metastases — pain palliation | ExAblate 2100 Bone MRgFUS (preferred); HAIFU for accessible lesions | MR thermometry for spinal lesions; experience at your specific site |
| Thyroid nodule — benign symptomatic | Echopulse or SONICTAC USgHIFU | Annual thyroid nodule volume; laryngoscopy assessment protocol; VRN monitoring |
| Essential tremor / Parkinson's tremor | ExAblate Neuro tcMRgFUS (only appropriate system) | SDR calculation protocol; bilateral tremor cases managed how |
| Breast tumour — small, inoperable | HAIFU JC or dedicated breast HIFU system | Tumour-to-skin distance protocol; post-treatment biopsy confirmation practice |
HIFU Platform Landscape in Numbers
Key figures that contextualise the global and China-specific HIFU infrastructure.
- 100,000+Patients treated on HAIFU systems globallyThe HAIFU JC and affiliated systems represent the world's largest single-platform HIFU clinical experience, predominantly in China.
- 200+HAIFU-equipped centres in ChinaMore than 200 hospitals across China's Tier 2 and Tier 3A hospitals operate HAIFU systems — China's HIFU access per capita is unmatched globally.
- 1,024Transducer elements in ExAblate Neuro phased arrayEach element receives an individually calculated phase delay to compensate for skull acoustic aberration — enabling sub-millimetre targeting through intact bone.
- 9Major commercial HIFU platforms referenced in this guideThe HIFU device landscape is fragmented — each platform has different regulatory approvals, clinical evidence, and optimal indications.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the physics foundations to disease-specific clinical applications.
- HIFU Therapy — Complete Treatment Guide
- What Is HIFU? Non-Invasive Focused Ultrasound Explained
- HIFU Physics: How Acoustic Focusing Destroys Tissue
- HIFU for Uterine Fibroids: MRgFUS Complete Guide
- Transcranial MRgFUS: Brain Tumours and Neurological Conditions
- HIFU for Prostate Cancer: Whole-Gland and Focal Treatment
Frequently Asked Questions
Common questions from patients trying to understand which HIFU system is relevant to their case.
Platform Selection Questions
The centre I am considering uses a HAIFU system — is this as good as MRgFUS?
For the indications where HAIFU has the strongest evidence — liver cancer, pancreatic cancer, uterine fibroids, and bone metastases in accessible locations — the HAIFU system achieves outcomes comparable to MRgFUS, with the advantage of higher operator experience volume in China. The principal advantage MRgFUS holds is real-time MR thermometry — direct focal temperature measurement that USgHIFU systems (including HAIFU) cannot provide. This advantage is most clinically important for spinal bone metastases (where cord temperature monitoring is critical) and transcranial neurological procedures. For liver, pancreas, and uterine applications, HAIFU's limitations in temperature monitoring are largely compensated for by experienced operator interpretation of ultrasound tissue change patterns and the large published evidence base.
How do I verify whether a centre is actually experienced with the HIFU system they operate?
Ask the centre three specific questions: (1) How many procedures do you perform per year specifically on your HIFU system for my indication — not 'HIFU procedures' generically? (2) Can you share your centre's outcome data for this indication, or point to a published series from your institution? (3) Which operator will perform my procedure, and what is their individual caseload? A centre that cannot answer all three clearly and specifically is a centre to approach with caution regardless of which hardware they have installed. CancerFax performs this vetting as part of centre selection and only refers patients to centres that can provide satisfactory answers to all three questions.
Is there a newer, better HIFU system coming that I should wait for?
The HIFU landscape is actively developing — particularly in blood-brain barrier opening systems, MRI-guided transurethral prostate platforms (TULSA-PRO), and next-generation transcranial phased arrays. However, waiting for the 'next system' is rarely the right clinical decision for a patient with an active cancer or disabling neurological condition. The systems currently available — HAIFU, ExAblate, Ablatherm, Sonablate — have substantial published evidence and large operator experience bases. The benefits of acting on an established, mature system now almost always outweigh the theoretical advantages of a system that may be 3–5 years from widespread clinical availability.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure Which HIFU System Is Right for You?
CancerFax reviews your tumour type, location, and clinical history to identify which HIFU platform — and which centre operating that platform — is most appropriate for your case, and coordinates the referral and consultation.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.